跳至主要内容
临床试验/JPRN-UMIN000002641
JPRN-UMIN000002641招募中未知

A open label, randomized, controled trial to assess the usefulness of telmisartan in patients with type 2 diabetes, obesity, and NAFLD. - Matsuyama Shimin Hospital, Hypertension therapy for patients with type2 diabetes, obesity and NAFLD. (MADONNA study)

MATSUYAMA SHIMIN HOSPITA0 个研究点目标入组 50 人开始时间: 2009年10月21日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Patients whose fatty liver is difficult to evaluate. (A heavy drinker, other liver diseases, etc.) 2) Patients requiring hospitalization to attain glycemic control. 3) Patients judged inadequate to participate in this study by their physician.

研究者

发起方
MATSUYAMA SHIMIN HOSPITA

相似试验

招募中
不适用
A open label, randomized, controled trial to assess the utility of Pitavastatin for patients with type2 diabetes and obesity in Matsuyama Shimin Hospital.Type 2 diabetic patients with hyperlipidemia
JPRN-UMIN000007024MATSUYAMA SHIMIN HOSPITA50
已完成
不适用
An open-label, randomized, controlled trial to assess the efficacy and safety of teprenone in chronic hepatitis C patients concurrent with chronic gastritis treated with peginterferon alpha-2b plus ribavirin.Chronic hepatitis C patients with genotype 1 and high viral load (&gt= 5 Log IU/mL) concurrent with chronic gastritis.
JPRN-UMIN000001391Department of Gastroenterology and Hepatology, Okayama University Hospital200
尚未招募
Unknown
A trial to assess the role of serial physical examination for well appearing babies at risk of sepsis
CTRI/2024/04/066566ONE
已完成
不适用
An open-label randomized controlled trial to assess the efficacy and safety of chronic hepatitis C and compensated cirrhosis patients with the prescribing pattern of vitaminD plus peginterferon alpha-2a /ribavirin.Chronic hepatitisC patients and compensated cirrhosis patients
JPRN-UMIN000008342Saitama Medical University80
已完成
不适用
An open-label randomized controlled trial to assess the efficacy and safety of chronic hepatitis C patients with vitaminD plus peginterferon alpha-2a /ribavirin.versus alfacalcidol plus peginterferon alpha-2a /ribavirin.Chronic hepatitis C patients with genotype 1 and high viral load (&gt= 5 Log IU/mL)
JPRN-UMIN000004210Saitama Medical University40